Cooper Companies (The) (COO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$69.59-1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · COO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -10.8% |
| Our one-year growth estimate | diamond | 5.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 16.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 26 industry peers
COO — litigation filed
Dated 2026-06-04
Other Events. As described in its June 4, 2026 press release, the Company recorded a charge as further described below. In December 2023, CooperSurgical, one of the Company’s two business units, initiated a voluntary recall of three specific lots of CooperSurgical’s LifeGlobal TM global ® embryo culture media that it had produced. Subsequently, claims and lawsuits in various U.S. and international jurisdictions were brought by individuals who generally allege that they suffered damages associ…
Why it matters: Higher margins show good execution and cost control.
Supportive ifOperating margin was above 27% in Q2.
Worry ifOperating margin reported at or below 27% for Q2.
Why it matters: A decrease in these charges would signal that the company is resolving its legal issues and moving forward. This could improve investor confidence.
Supportive ifLitigation charges are under $200 million in Q3.
Worry ifLitigation charges are $300 million or more in Q3.
Why it matters: More charges could hurt profits and cash flow. This may lower investor trust.
Worry ifNo new legal charges reported in the next earnings release.
Less concerning ifNew legal charges are over $50 million in the next earnings release.
Why it matters: News about the share buyback shows that management trusts the company's value.
Supportive ifManagement says they will increase the share buyback program.
Worry ifManagement pauses or cuts the share buyback program.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$100 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $257 loss on $10,000 · 2.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,005 loss on $10,000 · 30.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Organic growth above 5% would signal strong demand and effective execution. This is key for investor confidence.
Supportive ifQ3 revenue grew more than 5% without any outside help.
Worry ifQ3 revenue grew less than 5% without any outside help.
Why it matters: Hitting this target shows strong cash flow. It helps fund operations and growth.
Supportive ifFree cash flow reported at $600 million or more for FY 2026.
Worry ifFree cash flow reported below $500 million for FY 2026.
Why it matters: This deal helps CooperSurgical grow its fertility products. It will also increase income.
Supportive ifThe deal will close after receiving all approvals.
Worry ifThe deal does not close because of regulatory or other problems.
Why it matters: Higher charges may hurt profits and cash flow. This could lower investor confidence.
Worry ifCharges from lawsuits were above $300 million.
Less concerning ifCharges from lawsuits were below $300 million.
Why it matters: Hitting this growth target shows the company can grow even with challenges.
Supportive ifQ3 revenue growth exceeds 5% on an organic basis.
Worry ifQ3 revenue growth falls below 3.5% on an organic basis.
Why it matters: His experience may improve strategy and operations. This could help long-term value.
Supportive ifPeople liked the board after Keel was appointed.
Worry ifThere was negative feedback or issues with board decisions after the appointment.
Why it matters: Hitting the $600-$625 million target matters for future investments and profits.
Supportive ifManagement reaffirms or raises free cash flow guidance for FY 2026.
Worry ifManagement lowers free cash flow guidance for FY 2026 below $600 million.